# ModernaTX, Inc.: Phase 4 study closed enrollment, 30000 enrolled (SARS-CoV-2)

**Score:** 60/100

| Field | Value |
|---|---|
| Sponsor | ModernaTX, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) |
| NCT ID | NCT07266558 |
| Phase | Phase 4 |
| Status | active not recruiting |
| Conditions | SARS-CoV-2 |
| Intervention types | biological |
| Target enrollment | 30000 |
| Site countries | United States |
| Posted | 2025-12-05 |
| Planned start | 2025-11-26 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-09-28 |
| Last update posted | 2026-09-28 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- 30000 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07266558). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.